VinodKumarRustgiMDMBA

PubMed

• Outcomes and risk factors for mortality in clostridioides difficile infection in patients with NAFLD and NASH.
  Ankoor H Patel, Gaurav N Pathak, Alexander Chen, Patricia Greenberg, Natale Mazzaferro
  Annals of Hepatology. 2024-05-05
• Pathophysiology of Hepatic Encephalopathy: A Framework for Clinicians.
  Alexander Chen, Christopher Tait, Carlos Minacapelli, Vinod Rustgi
  Clinics in Liver Disease. 2024-05-01
• 7 citations
  Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease ci...
  Mohamed I Elsaid, Na Li, Stephen A Firkins, Vinod K Rustgi, Electra D Paskett
  Alimentary Pharmacology & Therapeutics. 2024-05-01

Journal Articles

• New Perspectives and Advances in Risk-Factor Assessment, Diagnosis, and Treatment of Hepatitis C.  
  Rustgi VK, Practical Gastroenterology
• Hepatitis C virus treatment related anemia is associated with higher sustained virologic response rate.  
  Sulkowski MS, Shiffman ML…Rustgi V…et al, Gastroenterology;139 (5): 1602-11, 1611.e1
• Racial differences in hepatitis C treatment eligibility.  
  Melia MT…Rustgi VK…et al, Hepatology: 54(1): 70-8
• Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3.  
  Thompson AJ…Rustgi VK…et al, Epub
• Peginterferon alfa-2a with ribavirin for treatment of hepatitis C infection.  
  McHutchinson…Rustgi VK…et al, N Engl J Med; 361 (6):580-93
• A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma.  
  Gish RG, Gordon SC, Nelson D. Rustgi V, Rios I, Hepatology International
• Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy.  
  Poynard T… Rustgi VK… et al, Gastroenterology;146(5):1618-28
• Telapravir with peginterferon and ribavirin for chronic HCV genotype 1 infection.  
  McHutchinson JG, Everson GT… Rustgi, VK… et al, N Engl J Med; 360(18): 1827-38
• Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C.  
  Rodriguez-Torres M… Rustgi VK… et al, N Engl J Med;360(3):257-67
• Thymalfasin for the treatment of chronic hepatitis C infection.  
  Rustgi, VK, Expert Rev Anti Infect Ther; 3(6):885-92
• Combination therapy of thymalfasin (thymosin-alpha 1) and peginterferon alfa-2a in patients with chronic hepatitis C virus infection who are nonresponders to standard ...  
  Rustgi, VK, J Gastroenterol Hepatol; 19(12):S76-8
• Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy.  
  Shiffman ML, Hofmann CM, Gabbay J….Rustgi V, Am J Gastroenterol; 95 (10): 2928-35
• The AST Statement on Ethics in Organ Transplantation.  
  Brennan DC, Pomlanovich SJ, Lash J, Rustgi V, et al, AST Newsletter 5(4):8
• The disposition of 6-deoxyayclovir, a xanthine oxidase activated prodrug of acyclovir, in the isolated perfused rat liver.  
  Jones DB, Rustgi VK, Kornhauser DM, Hoofnagle JH, Jones EA, Hepatology (2): 345-348
• Interferon Alpha-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C.  
  McHutchison JG, Gordon SC, Schiff ER, Shiffman MLK, Lee WM, Rustgi VK, et al, NEJM 339(21): 1485-1492
• Lymphoblastoid Interferon-alpha N1 Improves a Long-term Response to a Six-month Course of Treatment in Chronic Hepatitis C Compared With Recombinant Interferon-alpha 2...  
  Farrell GC, Bacon BR, Goldin RD…Rustgi VK… and the Clinical Advisory Group for the Hepatitis C Comparative Study, Hepatology 27(2): 1121-1127
• Performance Characteristics and Results of a Large Scale Screening Program for Viral Hepatitis and Risk Factors Associated with Exposure to Viral Hepatitis B and C—The...  
  Kaur S, Rybicki L, Bacon BR, Gollan JL, Rustgi VK, Carey WD, and the National Hepatitis Surveillance Group, Hepatology 24(5):979-986
• Epstein-Barr Viral Infection and Post-Transplant Lymphoproliferative Disorders (PTLD).  
  Rustgi VK, Liver Transplantation and Surgery 1(5)(Suppl):100-108
• Absolute Peripheral Blood Eosinophilia: An Early Marker for Rejection in Clinical Liver Transplantation.  
  Manzarbeitia C, Rustgi V, Jonsson J, Oyloe VK, Transplantation 59(9):1358-1360
• Comparative Studies of the Immunogenicity and Safety of Engerix-B Administered at 0, 1, 2 and 12 Months and Recombivax HB Administered at 0, 1 and 6 Months in Healthy ...  
  Rustgi VK, Schleupner CJ, Krause DS, Vaccine 13(17):1665-1668
• Management of Hemobilia Following Liver Biopsy and Liver Transplant Recipients.  
  Manzarbeitia C, Jonsson J, Rustgi V, et al, Transplantation 56(6):1545-1547
• Omeprazole is Superior to Ranitidine Plus Metaclopramide in Short-Term Treatment of Erosive Esophagitis.  
  Robinson M, Decktor DL, Maton PN...Rustgi V, Kovacs T, Aliment. Pharmacol. Ther; 7:67-73
• P53 Mutation in Hepatocellular Carcinoma After Aflatoxin Exposure.  
  Ozturk M... Rustgi VK... et al, Lancet 338:1356-59
• GI and Hepatobiliary Disorders in Pregnancy.  
  Rustgi V, Practical Gastroenterology
• The disposition of 6-deoxycyclovir, a xanthine oxidase-activated prodrug of acyclovir, in the isolated perfused rat liver.  
  Jones DB, Rustgi VK, Kornhauser DM, et al, Hepatology 7(2): 345-8
• Join now to see all

Books/Book Chapters

• Gastrointestinal and Hepatic Complications in Pregnancy. 
  Rustgi VK, Cooper JNEditors: Rustgi VK, Cooper JN.John Wiley & Sons, New York
• Endoscopy in the pregnant patient. 
  Rustgi VK, Cooper JN, Colcher H
• Cirrhosis and pregnancy. 
  Rustgi VK
• Hepatic Carcinoma. 
  Rustgi VKEditors: Rustgi VK.W.B. Saunders, Philadelphia
• Epidemiology of Hepatocellular Carcinoma. 
  Rustgi VK
• Hepatic Diseases. 
  Rustgi VKW.B. Saunders, Philadelphia, PA
• Liver Disease in Pregnancy. 
  Rustgi VK
• Gastrointestinal Infections in the Tropics. 
  Rustgi VKEditors: Rustgi VK.S. Karger Ag, Basel
• The Liver in Systemic Disease. 
  Rustgi VK, Van Thiel DHRaven Press, New York
• The Liver in Pregnancy. 
  Rustgi VK, Fagiuoli S and Van Thiel DH
• Viral Hepatitis and Liver Disease. 
  Chapter: Alpha-Interferon Therapy in Patients with Decompensated Chronic Type B Hepatitis 
  Page 840 - 843Kassianides C, DiBisceglie AM, Hoofnagle JH, Mullen K, Peters M, Rustgi VK, et alEditors: Zuckerman A.Alan R. Liss, Inc, New York
• Gastrointestinal Emergencies. 
  Chapter: The Acute Abdomen in Pregnancy 
  Page 522 - 527Rustgi VKEditors: Taylor M, Gollan JL, Peppercorn MA, Steer ML, Wolfe MM.Williams and Wilkins Co, Baltimore
• Liver Disease: Diagnosis and Management. 
  Chapter: The Liver and Systemic Diseases 
  Rustgi VKEditors: Bacon BR, Di Bisceglie AM.Churchill Livingstone
• Medical Management of Liver Disease. 
  Chapter: Management of Liver Disease in Pregnancy 
  Rustgi VKEditors: Krawitt EL.Marcel Dekker, Inc
• Management of Chronic Viral Hepatitis. 
  Chapter: Treatment of Chronic Hepatitis C: Transplant Recipients 
  Marino G, Rustgi VKEditors: Gordon SC.Published by Marcel Dekker
• Liver Transplantation in Clinical Management of the Transplant Patient. 
  Johnson LB, Plotkin JS, Kuo PC, Lauren JC, Rustgi VKEditors: Kuo PC, Schroeder RA, Johnson LB.Arnold Publishers, London
• Join now to see all

Abstracts/Posters

• The effect of rat gamma interferon on antipyrine metabolism by the isolated perfused rat liver.
  Rustgi VK, Suou T, Jones DB, Lisker-Melman M, Vergalla J, Jones EA, Hoofnagle JH, AFCR National Meetings; Clinical Research, 35 (3): 414A, San Diego, CA
• Liver Transplantation for the Alcoholic Patient.
  Rustgi VK, Transplant Forum pp. 2-4
• Chronic domiciliary respiratory support by portable positive pressure ventilators.
  Tsou E, Waldhorn R, Rustgi VK, Am. Rev. Resp. Dis. 127: 125
• Hepatitis and the acquired immunodeficiency syndrome.
  Rustgi VK, Hoofnagle JH, Macher AM, et al, AGA National Meetings, Gastroenterology 86: 1226, New Orleans
• Naltrexone in the irritable bowel syndrome.
  Rustgi VK, Maguire M, Cooper JN, et al, Gastroenterology 88: 1563
• Upper gastrointestinal endoscopy in the pregnant patient.
  Rustgi VK, Colcher H, Cooper JN, Gastroenterology 88: 1563
• HTLV-III inhibition by gastric juice.
  Rustgi VK, Slaff JI, Salahuddin SZ, AGA National Meetings, Gastroenterology 90: 1610, San Francisco
• Randomized controlled trial of a four month course of recombinant human alpha interferon in patients with chronic type B hepatitis.
  DiBisceglie AM, Hoofnagle JH, Peters M, Mullen KD, Jones DB, Rustgi VK, Avigan MI, Park Y, Waggoner J, Jones EA, ISIR meeting on the interferon system in Finland, J of Interferon Research 6 (suppl.): 33
• Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon.
  Hoofnagle JH, Mullen KD, Jones DB, Rustgi VK, DiBisceglie AD, Peters MG, Waggoner JG, Park Y, Jones EA, Hepatology 6: 1221
• Localization of the P-450 system in liver by in-situ hybridization.
  Rustgi VK, Jones DB, DiBisceglie AM, Hoofnagle JH, Jones EA, Hepatology 6: 1220
• Inhibition of hepatitis B virus replication by recombinant human gamma interferon.
  DiBisceglie AM, Rustgi VK, Kassianides C, et al, International Symposium on Viral Hepatitis,, School of Hygiene and Tropical Health, London
• Alpha interferon treatment of patients with decompensated chronic hepatitis B.
  Kassianides C, DiBisceglie AM, Rustgi VK, et al, International Symposium on Viral Hepatitis, London School of Hygiene and Tropical Health
• Antiviral therapy of chronic viral hepatitis.
  Hoofnagle JH, DiBisceglie AM, Rustgi VK, et al, International Symposium on Viral Hepatitis, London School of Hygiene and Tropical Health
• Successful treatment of hepatitis B virus-associated glomerulonephritis with recombinant human alpha-interferon.
  Lisker-Melman M, Webb D, DiBisceglie AM, Kassianides C, Martin P, Rustgi VK, et al, Hepatology 8: 1269
• P53 Hotspot mutation in hepatocellular carcinoma is linked to aflatoxin exposure.
  Ozturk M, Rustgi V, Sarosi I, Hepatology 14: 94A
• Incidence of post-transfusion hepatitis C in ex-premature infants.
  Rustgi VK, Leibowitz I, Hepatology 14: 218A
• Detection of HCV specific antigens in semen of patients with non-A, non-B hepatitis - direct evidence for potential sexual transmission of HCV.
  Kotwal GJ, Rustgi VK, Baroudy BM, Hepatology 14: 210A
• Persistence of HCV genomes in patients treated with alpha-interferon.
  Liang TJ, Rustgi VK, Hepatology 14: 211A
• Collagen IV levels in hepatitis C patients treated with alpha-interferon.
  Rustgi VK, Mushahwar I, Hepatology 16: 4, part 2, 220A
• Biliary stone analysis in recurrent pyogenic cholangitis.
  Rustgi VK, Khuroo MS, Hepatology 16: 2, part 2, 265A
• Safety and Immunogenicity of Immune Globulin (IG) Versus Two Dosing Schedules of an Inactivated Hepatitis A (HA) Vaccine in Healthy Adult Travelers.
  Sack M, Rustgi V, Levison M, Krause D, Third International Conference on Travel Medicine, Paris, France
• A Comparative Study of the Immunogenicity and Safety of Engerix-B at 0, 1, 2, and 12 months and Recombivax HB at 0, 1 and 6 Months.
  Rustgi V, Schleupner C, Bellak C, Krause D, ICAAC Meeting, New Orleans
• Low Dose Acetaminophen Resulting in Fulminant Hepatic Failure.
  Rustgi VK, Manzarbeitia C, Jonsson J, et al, Hepatology 18: 321A
• Incidence of Hepatitis E in Kashmir.
  Rustgi VK, Khuroo MS, Dawson GJ, Mushahwar IK, Hepatology 18: 253A
• Management of ABO-Incompatible Grafts in Fulminant Hepatic Failure.
  Manzarbeitia C, Rustgi VK, Jonsson J, et al, The International Liver Transplant Society Meetings
• Join now to see all

Other

• A phase 2 dose-escalation study of albuferon combined with ribavirin in non-responders to prior interferon based therapy for chronic hepatitis C infection. 
  Reddy KR, Rustgi VK, Zeuzem S, Gane E, Lim SG, Jia JD, Belanger B, George S, Harb G, annual European Association for the Study of the Liver Meeting
  http://www.easl.ch/easl2006/program/SessionIndex.asp
• Valopicitabine (NM283), alone or with peg-interferon, compared to peg Interferon/Ribavirin (PEGIFN/RBV) retreatment in hepatitis C patients with prior non-response to ... 
  Afdhal N, O’Brien C, Godofsky E, Rodriguez-Torres M, Pappas SC, Pockros P… Rustgi VK… et al, annual European Association for the Study of the Liver Meeting
  http://www.easl.ch/easl2006/program/SessionIndex.asp
• Pre-dosing taribavirin prior to combination therapy with pegylated interferon alfa-2B versus standard combination dosing: 24-week interim results examining safety and ... 
  Palmer M, Rubin R, Rustgi VK, Li D & Murphy B, annual European Association for the Study of the Liver Meeting
  http://www.easl.ch/liver-meeting/program/SessionIndex.asp
• Antiviral activity and changes in B-lymphocyte stimulator protein levels during treatment with AlbInterferon alfa-2b/Ribavirin in prior interferon-therapy nonresponders. 
  Rustgi VK, Nelson D, Balan V, Sulkowski M, McHutchinson JG, Fiscella M, et al, annual European Association for the Study of the Liver Meeting
  http://www.easl.ch/liver-meeting/program/SessionIndex.asp
• Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of Nitazoxanide plus Peginterferon and Ribavirin in HCV Genotype 1 Patients: Interim Analysis Shows Increase... 
  Bacon B, … Rustgi VK, Keeffe E, annual European Association for the Study of the Liver Meeting
  http://www.easl.ch/liver-meeting/program/SessionIndex.asp
• Join now to see all